GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

sunobinop   Click here for help

GtoPdb Ligand ID: 14125

Synonyms: IMB-115 | IMB115 | S 117957 | V117957
Compound class: Synthetic organic
Comment: Sunobinop is a selective NOP (nociceptin/orphanin FQ peptide) receptor partial agonist [1]. It has sleep promoting and wake suppressing actions in preclinical models.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 73.21
Molecular weight 435.56
XLogP 4.34
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC2=C(C=C1)N(C3C[C@@H]4CCC[C@H](C3)N4C5C[C@H]6CCC[C@@H](C6)C5)C(=O)C(=N2)C(=O)O
Isomeric SMILES C1C[C@H]2C[C@H](C1)CC(C2)N3[C@@H]4CCC[C@H]3CC(C4)N5C6=CC=CC=C6N=C(C5=O)C(=O)O
InChI InChI=1S/C26H33N3O3/c30-25-24(26(31)32)27-22-9-1-2-10-23(22)29(25)21-14-18-7-4-8-19(15-21)28(18)20-12-16-5-3-6-17(11-16)13-20/h1-2,9-10,16-21H,3-8,11-15H2,(H,31,32)/t16-,17-,18-,19+,21?/m0/s1
InChI Key COTYYZPYDJKKIS-MCXOOUIESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Sunobinop (V117957) is a candidate therapeutic for indications including alcohol use disorder and insomnia.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04035200 Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation Phase 2 Interventional Imbrium Therapeutics
NCT06545916 Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder Phase 2 Interventional Imbrium Therapeutics